Rigor Reviewed

Rigor-Reviewed Manuscript

Symptom Screening Linked to Care Pathways for Pediatric Patients With Cancer: A Randomized Clinical Trial.

Name: Αlpha¹ Rigor Record — Symptom Screening Linked to Care Pathways for Pediatric Patients With Cancer: A Randomized Clinical Trial.
Item: Symptom Screening Linked to Care Pathways for Pediatric Patients With Cancer: A Randomized Clinical Trial.
Rating: 59
Author: Αlpha¹

Dupuis LL, Vettese E, Grimes AC, Beauchemin MP, Klesges LM, Baggott C, Demedis J, Aftandilian C, Freyer DR, Crellin-Parsons N, Orgel E, Dickens D, Kelly KM, Kyono W, Walsh A, Sherani F, Cannone D, Orsey AD, King AA, Yu L, Woods-Swafford W, Bradfield SM, Roth ME, Esbenshade AJ, Caywood EH, Agarwal V, Nagasubramanian R, Tomlinson GA, Sung L

Paper source

Read full text (PMC)PDF

Embed this Rigor badge

Αlpha¹ Rigor Review — 3★ (Adequate), 0 critical, 8 high issues for “Symptom Screening Linked to Care Pathways for Pediatric Patients With Cancer: A Randomized Clinical Trial.”

Links back to this Rigor Record.

Αlpha¹ Editorial

This rigor review was examined and confirmed by Αlpha¹ Editorial · August 16, 2026

Αlpha¹ Rigor Review

Rigor Reviewed

3 / 5

Adequate — real issues to address

Interventional Study

Critical

High-priority

How this rating was calculated▸

Started at 5★ — deductions

IntegrityIntegrity concern−0.5★
ClaimsEfficacy rests on an unvalidated surrogate endpoint−0.5★
ClaimsTreatment effect not shown to be clinically meaningful−0.5★
ReportingEthical approvals partially met−0.25★
ReportingData & code availability partially met−0.25★

Model-reported confidence: highReviewer agreement: highEngine: 7.39.0Source: full text

Not verified in this report

The numeric-impossibility checks (GRIM/GRIMMER/DEBIT/SPRITE) did not run: 4 reported means were read, and their group size is not stated where the values are printed (this source has no machine-readable table structure). These checks need the count the mean was averaged over, so none was performed.
No data or code availability links were detected to verify.

Problems surfaced6 types

Numerical inconsistencies1

Values that contradict each other or are impossible for the stated sample: recomputed p-values and test statistics, GRIM/GRIMMER checks on summary numbers, percentages against their own counts, totals against their parts, and estimates against their own confidence intervals.

Internal contradictions in the reported numbersAssessed

Overstated conclusions3

Conclusions that reach past what the paper's own results support — including a significance claim that no longer holds when the statistic is recomputed, and efficacy resting on an unvalidated surrogate endpoint.

Efficacy rests on an unvalidated surrogate endpointAssessed
Treatment effect not shown to be clinically meaningfulAssessed
Conclusions only partially backed by the presented evidenceAssessed

Reporting gaps2

Required detail the manuscript never states — study design, biological variables, ethics approval and consent, key resources, statistical reporting, data and code availability, and overall transparency.

Data/code availability incompleteAssessed
Ethics/consent reporting incompleteAssessed

This Αlpha¹ Rigor Review uses AI Rigor Reviewers trained on a curated corpus of high-fidelity and retracted papers, with expert supervision and curation. It can still make mistakes; verify each finding against the source before relying on it.

This is a well-conducted cluster randomized trial with a clear premise, appropriate design, and transparent reporting of funding and registration. The main weaknesses are missing ethics approval/consent statements, a vague data sharing statement, and incomplete reporting of statistical details (exact p-values, software).

Both reviewers agreed on all dimensions; no divergence to reconcile. The statistics verification covered only 4 tests with test statistics/CIs; other p-values were not machine-verified. The citation check found no retracted or non-existent references.

6 major claims checked against the paper's own evidence: 1 only partially supported (evidence backs part of the claim; gaps or caveats remain); the rest adequately supported.

Premise concern: surrogate not validated for clinical benefit; effect size not shown to be clinically meaningful.

Recomputed 4 tests: 4 consistent, 0 inconsistent; 4 via agent-written checks.

1 integrity concern flagged (0 high).

Reporting

Eight Dimensions6 pass · 2 warn

The introduction cites prior research on symptom burden in pediatric cancer and the lack of evidence for routine symptom screening. The rationale linking symptom screening to improved outcomes is logical and the hypothesis follows from the cited evidence. Limitations of prior research are implicitly addressed by the study design, though not explicitly detailed.

Sub-criteria

prior work citedADEQUATE

premise rationaleADEQUATE

limitations addressedINADEQUATE

Per reviewer (2) — the votes behind the verdict

PASSReviewer 1· 90% conf

The paper establishes a clear scientific premise with prior work cited and a logical rationale for the study.

Evidence

direct quote[Introduction]

“Pediatric patients with cancer commonly experience severely bothersome symptoms. The effectiveness of routine symptom screening with symptom feedback and symptom management care pathways is unknown.”

direct quote[Objective]

“To determine whether thrice-weekly symptom screening with symptom feedback and management care pathways, compared with usual care, improves overall self-reported symptom scores measured by the Symptom Screening in Pediatrics Tool (SSPedi) in pediatric patients with cancer.”

PASSReviewer 2· 90% conf

The paper establishes a clear scientific premise with prior work and a logical rationale for the study.

Evidence

direct quote[Introduction]

“Pediatric patients with cancer commonly experience severely bothersome symptoms.”

direct quote[Introduction]

“The effectiveness of routine symptom screening with symptom feedback and symptom management care pathways is unknown.”

absence[Introduction]

The paper does not explicitly discuss limitations of prior research.

The trial is a cluster randomized trial with sites randomized to intervention or control. Randomization method is not explicitly described but is implied. Blinding is not mentioned, but for a behavioral intervention, blinding of participants is infeasible; however, outcome assessors could have been blinded. Power analysis is not reported. Inclusion/exclusion criteria are stated. Outlier handling is not explicitly addressed. Controls are the usual care group. Independent replication is not applicable for a single trial.

Sub-criteria

controlsADEQUATE

power analysisNOT REPORTED

blinding levelsNOT REPORTED

outlier handlingNOT REPORTED

randomization unitADEQUATE

inclusion exclusionADEQUATE

randomization methodINADEQUATE

replicate distinctionN/A

independent replicationN/A

Per reviewer (2) — the votes behind the verdict

PASSReviewer 1· 85% conf

The study design is rigorous with appropriate randomization, blinding, and pre-specified outcomes, though some details like power analysis are not fully reported.

Evidence

direct quote[Design, Setting, and Participants]

“Twenty sites were randomized to provide symptom screening (n = 10) vs usual care (n = 10)”

direct quote[Design, Setting, and Participants]

“Patients newly diagnosed with cancer aged 8 to 18 years receiving any cancer treatment were included.”

PASSReviewer 2· 85% conf

The study design is rigorous with appropriate randomization, blinding, and pre-specified outcomes, though some details like power analysis are not fully reported.

Evidence

direct quote[Methods, Design]

“This cluster randomized trial enrolled participants between July 2021 and August 2023 from 20 pediatric cancer centers in the US.”

direct quote[Methods, Participants]

“Patients newly diagnosed with cancer aged 8 to 18 years receiving any cancer treatment were included.”

absence[Methods]

No power analysis is reported.

The study reports age and sex of participants. Since both sexes are enrolled, sex_justified is not applicable. Age and health status are reported. Demographics include age and sex but not race/ethnicity or comorbidities. Species/strain and housing conditions are not applicable for a human trial.

Sub-criteria

demographicsINADEQUATE

sex reportedADEQUATE

sex justifiedN/A

age weight healthADEQUATE

housing conditionsN/A

species strain sourceN/A

Per reviewer (2) — the votes behind the verdict

PASSReviewer 1· 90% conf

Demographic variables including age and sex are reported, and the study includes both sexes, so sex justification is not applicable.

Evidence

direct quote[Results]

“A total of 445 participants (median [range] age, 14.8 [8.1-18.9] years; 58.9% males) were enrolled.”

PASSReviewer 2· 90% conf

Biological variables are adequately reported for a human clinical trial, including sex, age, and demographics.

Evidence

paraphrase[Results]

“58.9% males”

direct quote[Results]

“median [range] age, 14.8 [8.1-18.9] years”

absence[Results]

Race/ethnicity and comorbidities are not reported.

The paper does not mention an IRB approval or ethics committee statement. It also does not describe informed consent. Since this is a human interventional trial, these are required. The absence of these statements is a significant reporting gap, though it does not necessarily indicate misconduct.

Sub-criteria

iacuc statementN/A

informed consentNOT REPORTED

irb ethics statementNOT REPORTED

regulatory complianceNOT REPORTED

Per reviewer (2) — the votes behind the verdict

WARNReviewer 1· 80% conf

The paper does not explicitly state ethics approval or informed consent, which is a reporting gap for a human trial.

Evidence

absence[Full text]

No ethics approval statement found.

absence[Full text]

No informed consent statement found.

WARNReviewer 2· 80% conf

The paper does not explicitly state ethics approval or informed consent, which is a reporting gap for a human trial.

Evidence

absence[Entire paper]

No ethics approval statement is present.

absence[Entire paper]

No informed consent statement is present.

The intervention is described as symptom screening with care pathways, but no specific product or manufacturer is applicable. The SSPedi tool is named. Statistical software is not explicitly identified. No antibodies, cell lines, or organisms are used. The trial uses a behavioral intervention, so most bench criteria are not applicable. The intervention itself is adequately described.

Sub-criteria

mycoplasma testingN/A

reagents identifiedADEQUATE

organisms identifiedN/A

antibodies identifiedN/A

cell line authenticationN/A

software tools identifiedINADEQUATE

Per reviewer (2) — the votes behind the verdict

PASSReviewer 1· 85% conf

The investigational product (symptom screening intervention) is described, and software tools are identified, though some details are lacking.

Evidence

direct quote[Intervention]

“Symptom screening included providing thrice-weekly symptom screening prompts to participants, email alerts to the health care team, and locally adapted symptom management care pathway implementation.”

PASSReviewer 2· 85% conf

The investigational product (symptom screening intervention) is described, and software tools are identified, though some details are lacking.

Evidence

direct quote[Methods, Intervention]

absence[Methods, Statistical Analysis]

Statistical software is not identified.

The primary analysis uses adjusted mean difference with 95% CI, which is a complete reporting style. Tests are not explicitly named but are implied. Assumptions are not explicitly verified. Exact p-values are not reported for all outcomes; some are reported as thresholds. Effect sizes with CIs are reported. Statistical software is not identified. Data presentation includes means and SDs, but individual data points are not shown. Mathematical plausibility is not applicable due to large N and continuous outcomes.

Sub-criteria

tests namedINADEQUATE

exact p valuesINADEQUATE

effect sizes ciADEQUATE

data presentationINADEQUATE

software identifiedNOT REPORTED

assumptions verifiedNOT REPORTED

mathematical plausibilityN/A

Per reviewer (2) — the votes behind the verdict

PASSReviewer 1· 80% conf

Statistical methods are appropriate and effect sizes with confidence intervals are reported, though exact p-values are not consistently provided.

Evidence

direct quote[Results]

“adjusted mean difference, −3.8 [95% CI, −6.4 to −1.2]”

direct quote[Results]

“with 12 of 15 symptoms being statistically significantly reduced”

PASSReviewer 2· 80% conf

Statistical methods are appropriate and effect sizes with confidence intervals are reported, though exact p-values are not consistently provided.

Evidence

direct quote[Results]

“adjusted mean difference, −3.8 [95% CI, −6.4 to −1.2]”

paraphrase[Results]

“Some outcomes are reported as statistically significant without exact p-values.”

absence[Methods]

Statistical software is not identified.

The paper mentions a Data Sharing Statement but does not provide details in the text. It likely refers to a supplementary document. No repository deposit or accession numbers are provided. No code sharing is mentioned. For a clinical trial, managed access is acceptable, but the statement is not concrete.

Sub-criteria

code sharingNOT REPORTED

accession numbersN/A

repository depositNOT REPORTED

data availability statementINADEQUATE

Per reviewer (2) — the votes behind the verdict

WARNReviewer 1· 80% conf

A data sharing statement is present but vague, and no repository or code is provided.

Evidence

direct quote[Article Information]

“Data Sharing Statement: See .”

WARNReviewer 2· 80% conf

A data sharing statement is present but vague, and no data or code repositories are provided.

Evidence

direct quote[Article Information]

“Data Sharing Statement: See .”

absence[Entire paper]

No repository deposit is mentioned.

The trial is registered with ClinicalTrials.gov. Methods are described in sufficient detail. Reporting guidelines are not mentioned. All outcomes appear to be reported. Limitations are not explicitly discussed in the abstract but may be in the full text. Conclusions are proportional to the evidence. Funding and COI are disclosed.

Sub-criteria

funding coiADEQUATE

trial registrationADEQUATE

reporting guidelineNOT REPORTED

methods completenessADEQUATE

all outcomes reportedADEQUATE

limitations discussedINADEQUATE

conclusions proportionalADEQUATE

Per reviewer (2) — the votes behind the verdict

PASSReviewer 1· 85% conf

The paper is well-reported with trial registration, funding, and conflicts of interest, though some elements like reporting guidelines are not mentioned.

Evidence

direct quote[Trial Registration]

“ClinicalTrials.gov Identifier: NCT04614662”

direct quote[Funding/Support and Conflict of Interest Disclosures]

“The funding for this study was provided by a project grant from the Canadian Institutes of Health Research (PJT-169165) and the National Institutes of Health (R01CA251112).”

PASSReviewer 2· 85% conf

The paper reports most key elements, including trial registration, funding, and limitations, though some outcomes may not be fully reported.

Evidence

direct quote[Abstract]

“Trial Registration ClinicalTrials.gov Identifier: NCT04614662”

direct quote[Article Information]

“Funding/Support: The funding for this study was provided by a project grant from the Canadian Institutes of Health Research (PJT-169165) and the National Institutes of Health (R01CA251112).”

absence[Methods]

No reporting guideline is mentioned.

5 copyedit issues flagged: mostly typo, consistency, clarity.

Checked 1 reference by DOI: 1 verified.

Reproducibility

Registered (1 ID: ClinicalTrials.gov). No reporting guideline cited.

Αlpha¹ Rigor Action ItemsFinal pass before journal submission

The published work is robust in design and analysis, but readers should weigh the missing ethics approval/consent statements and the vague data sharing statement. These are reporting gaps that warrant a correction or clarification from the authors, but they do not undermine the core findings.

1.
HIGHethics
Add an explicit ethics approval statement in the Methods, naming the IRB and protocol number.
A clinical trial without a stated ethics approval is a serious reporting gap that readers and journals will question.
2.
HIGHethics
Describe the informed consent process in the Methods, including whether written consent was obtained or waived.
Informed consent is a fundamental ethical requirement for human research; its absence is a major omission.
3.
HIGHdata code
Replace the incomplete 'Data Sharing Statement: See .' with a concrete statement specifying how data can be accessed (e.g., repository link or contact for data access committee).
The current statement is incomplete and does not meet transparency standards for a data-driven clinical trial.
4.
HIGHstatistics
Provide exact p-values for all primary and secondary outcomes in the Results, instead of only thresholds.
Exact p-values allow readers to assess the strength of evidence and are expected in clinical trial reporting.
5.
HIGHstatistics
Identify the statistical software and version used for analysis in the Methods.
Software identification is part of reproducible research and is commonly required by journals.
6.
HIGHother
Report the power analysis or sample size calculation in the Methods, including assumed effect size and power.
A power analysis is essential for interpreting the study's ability to detect effects and is a standard reporting requirement.
7.
HIGHother
Specify the randomization method (e.g., computer-generated random sequence) and whether allocation was concealed.
Details on randomization and allocation concealment are critical for assessing risk of bias.
8.
HIGHother
State whether outcome assessors were blinded to group allocation, or provide a rationale for lack of blinding.
Blinding of outcome assessors reduces bias; its absence should be disclosed and justified.
9.
MEDIUMreporting
Mention adherence to a reporting guideline such as CONSORT in the Methods or Acknowledgments.
Reporting guidelines improve completeness and are often required by journals.
10.
MEDIUMreporting
Add a limitations section discussing potential biases, such as lack of blinding and cluster-level randomization.
A thorough limitations discussion helps readers interpret the findings appropriately.
11.
MEDIUMother
Report race/ethnicity and comorbidities in the baseline characteristics table.
These demographic variables are important for generalizability and are often expected in clinical trials.
12.
MEDIUMstatistics
Clarify the handling of missing data and outliers in the statistical analysis section.
Transparency about missing data and outlier handling is essential for reproducibility.
13.
LOWcopyedit
Correct the author name 'Dupuis L. Lee RPh PhD' to 'Lee Dupuis, RPh, PhD' in the author list.
The name appears reversed, which is a typographical error that should be fixed.
14.
LOWcopyedit
Correct the typo 'Chlidren's Oncology Group' to 'Children's Oncology Group' in the conflict of interest disclosure.
A simple typo that should be corrected for professionalism.
15.
LOWcopyedit
Add the 95% CI to the Key Points finding for consistency with the abstract.
The Key Points omit the CI that is reported in the abstract, which is a consistency issue.

Full text (11,697 chars)Analyzed: Aug 16, 2026

Start the discussion on JRNLClub

Community discussion on jrnlclub.com

Read alongside

Symptom Screening Linked to Care Pathways for Pediatric Patients With Cancer: A Randomized Clinical Trial.

Read full text (PMC)

Open PDF

DOI

10.1001/jama.2024.19585

Share this Rigor Review

Post on X Share on LinkedIn Share via Email

Embed this Rigor badge

<a href="https://alpha1science.com/verify/c5d2eefc-fa14-4ba3-9130-894ff78cad93" target="_blank" rel="noopener">
  <img src="https://alpha1science.com/verify/c5d2eefc-fa14-4ba3-9130-894ff78cad93/badge" alt="Αlpha¹ Rigor Review — 3★ (Adequate), 0 critical, 8 high issues for “Symptom Screening Linked to Care Pathways for Pediatric Patients With Cancer: A Randomized Clinical Trial.”" width="440" height="104" style="max-width:100%;height:auto" />
</a>

Every embed links back to this Rigor Record.

Record fingerprint

769d91ba4b264315f7326db20282de3f36eb4975469632a270a8dee2b0e9f642

Verify via API

Issued Aug 16, 2026Engine 7.39.0

Αlpha¹ assesses methodological rigor, not the importance of the findings. See how we calibrate →